Topical nitric oxide relieved pain and symptoms in chronic extensor tendinosis at the elbow

Hans J Kreder

_Evid. Based Med._ 2004;9;87- doi:10.1136/ebm.9.3.87

Updated information and services can be found at: [http://ebm.bmjjournals.com/cgi/content/full/9/3/87](http://ebm.bmjjournals.com/cgi/content/full/9/3/87)

These include:

**References**

This article cites 4 articles, 1 of which can be accessed free at: [http://ebm.bmjjournals.com/cgi/content/full/9/3/87#BIBL](http://ebm.bmjjournals.com/cgi/content/full/9/3/87#BIBL)

**Rapid responses**

You can respond to this article at: [http://ebm.bmjjournals.com/cgi/eletter-submit/9/3/87](http://ebm.bmjjournals.com/cgi/eletter-submit/9/3/87)

**Email alerting service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**

Articles on similar topics can be found in the following collections

- Other Rheumatology (1452 articles)

**Notes**

To order reprints of this article go to: [http://www.bmjjournals.com/cgi/reprintform](http://www.bmjjournals.com/cgi/reprintform)

To subscribe to _Evidence-Based Medicine_ go to: [http://www.bmjjournals.com/subscriptions/](http://www.bmjjournals.com/subscriptions/)
Topical nitric oxide relieved pain and symptoms in chronic extensor tendinosis at the elbow


Clinical impact ratings GP/FP/Primary care ★★★★★☆

Q In patients with chronic extensor tendinosis at the elbow (tennis elbow), does topical nitric oxide improve outcome?

METHODS

Design: randomised controlled trial.

Allocation: (concealed)†.

Blinding: blinded [patients and outcome assessors].*

Follow up period: 6 months.

Setting: Sydney, New South Wales, Australia.

Patients: 86 patients (95 elbows) who were 30–74 years of age (median age 46 y, 51% women) and had extensor tendinosis for >3 months. Exclusion criteria: pregnancy, previous surgery, dislocation of the affected wrist or elbow, distal neurological signs, or a local corticosteroid injection in the previous 3 months.

Intervention: 43 patients were allocated to a nitric oxide transdermal patch (1/4 of a 5 mg per 24 hour Nitro-dur patch, Schering-Plough, Sydney, Australia). 43 patients received a matching placebo transdermal patch. Patients also received 24 paracetamol tablets (500 mg/tablet) to use as needed and were instructed in a tendon rehabilitation programme.

Outcomes: Patient rated elbow pain (0–4 [severe]) at rest, with activity, or at night; local epicondylar and tendon tenderness (0 to 3 [severe]); and wrist extensor mean peak force and mean total work.

Patient follow up: 86% (analysis was by intention to treat).

* See glossary.
† Information provided by author.

MAIN RESULTS

The nitric oxide group had a greater decrease in elbow pain with activity at week 2 (p = 0.01), a greater decrease in lateral epicondylar and tendon tenderness at weeks 6 (p = 0.02) and 12 (p = 0.02), and a greater increase in mean peak force at week 24 (p = 0.03) and mean total work at week 24 (p = 0.03) than did patients in the placebo group. More patients in the nitric oxide group than the placebo group were asymptomatic during activities of daily living at week 24 (table).

CONCLUSION

In patients with chronic extensor tendinosis at the elbow, topical nitric oxide led to clinical improvement.

Commentary

Many treatments have been used for lateral epicondylitis, but little evidence supports their long term effectiveness. Although it has been shown that steroid injections provide early pain relief for <6 weeks after treatment, no long term benefit has been shown, and detrimental effects may exist. A simple wait and see approach may still be the best long term strategy.

The study by Paoloni et al is a well designed double blind study that shows improvement in pain and tenderness in all patients (including the placebo group) over the 24 week study period. However, patients treated with nitric oxide showed greater improvement than the placebo group. Those receiving the intervention also experienced more side effects—most notably headaches. 65% of patients in the nitric oxide group reported side effects, which were severe enough in 12% (overall) to discontinue treatment.

Activity modification to minimise repetitive stress is recognised as the first step in the treatment of tennis elbow. A simple wait and see approach, perhaps combined with physiotherapy and oral or topical NSAIDs, should suffice for most acute cases. Nitric oxide treatment may have a role in the treatment of chronic tennis elbow. When considering its use, patients should be screened for contraindications to nitroglycerin and warned about side effects.

Hans J Kreder, MD, MPH, FRCS(C)
University of Toronto,
Sunnybrook & Women’s College Health Sciences Centre
Toronto, Ontario, Canada


Topical nitric oxide vs placebo for chronic extensor tendinosis at the elbow*

<table>
<thead>
<tr>
<th>Outcomes at 24 weeks</th>
<th>Nitric oxide</th>
<th>Placebo</th>
<th>RBI (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic during ADLs</td>
<td>81%</td>
<td>60%</td>
<td>35% (2.6 to 83)</td>
<td>5 (3 to 61)</td>
</tr>
</tbody>
</table>

*ADLs = activities of daily living. Other abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article.